Aquestive Therapeutics Files 8-K

TL;DR

AQST dropped an 8-K on Aug 6th covering financials and Reg FD. Check it out.

AI Summary

Aquestive Therapeutics, Inc. filed an 8-K on August 6, 2024, to report on its results of operations and financial condition, as well as to provide a Regulation FD disclosure. The filing also includes financial statements and exhibits. The company is incorporated in Delaware and is headquartered in Warren, NJ.

Why It Matters

This 8-K filing provides crucial updates on Aquestive Therapeutics' financial performance and regulatory disclosures, which are important for investors to assess the company's current standing.

Risk Assessment

Risk Level: low — This filing is a standard 8-K reporting financial results and regulatory disclosures, not indicating any immediate material adverse events.

Key Numbers

• 0001398733 — Central Index Key (Unique identifier for Aquestive Therapeutics, Inc.)
• 001-38599 — SEC File Number (SEC filing number for Aquestive Therapeutics, Inc.)

Key Players & Entities

• Aquestive Therapeutics, Inc. (company) — Registrant
• August 6, 2024 (date) — Date of Report
• Delaware (jurisdiction) — State of Incorporation
• Warren, NJ (location) — Principal Executive Offices
• MonoSol Rx, Inc. (company) — Former Company Name

FAQ

Key Financial Figures

• $0.001 — ich registered Common Stock, par value $0.001 per share AQST Nasdaq Global Market I

Filing Documents

• aqst-20240806.htm (8-K) — 31KB
• q22024-ex991earningsrelease.htm (EX-99.1) — 253KB
• q22024supplementalearnin.htm (EX-99.2) — 24KB
• aqstlogoa.jpg (GRAPHIC) — 14KB
• q22024supplementalearnin001.jpg (GRAPHIC) — 93KB
• q22024supplementalearnin002.jpg (GRAPHIC) — 332KB
• q22024supplementalearnin003.jpg (GRAPHIC) — 137KB
• q22024supplementalearnin004.jpg (GRAPHIC) — 84KB
• q22024supplementalearnin005.jpg (GRAPHIC) — 68KB
• q22024supplementalearnin006.jpg (GRAPHIC) — 44KB
• q22024supplementalearnin007.jpg (GRAPHIC) — 87KB
• q22024supplementalearnin008.jpg (GRAPHIC) — 95KB
• q22024supplementalearnin009.jpg (GRAPHIC) — 93KB
• q22024supplementalearnin010.jpg (GRAPHIC) — 80KB
• q22024supplementalearnin011.jpg (GRAPHIC) — 106KB
• q22024supplementalearnin012.jpg (GRAPHIC) — 69KB
• q22024supplementalearnin013.jpg (GRAPHIC) — 44KB
• q22024supplementalearnin014.jpg (GRAPHIC) — 116KB
• q22024supplementalearnin015.jpg (GRAPHIC) — 112KB
• q22024supplementalearnin016.jpg (GRAPHIC) — 40KB
• q22024supplementalearnin017.jpg (GRAPHIC) — 66KB
• q22024supplementalearnin018.jpg (GRAPHIC) — 75KB
• q22024supplementalearnin019.jpg (GRAPHIC) — 76KB
• q22024supplementalearnin020.jpg (GRAPHIC) — 60KB
• q22024supplementalearnin021.jpg (GRAPHIC) — 37KB
• 0001628280-24-035223.txt ( ) — 3122KB
• aqst-20240806.xsd (EX-101.SCH) — 2KB
• aqst-20240806_lab.xml (EX-101.LAB) — 21KB
• aqst-20240806_pre.xml (EX-101.PRE) — 12KB
• aqst-20240806_htm.xml (XML) — 3KB

02

Item 2.02 Results of Operations and Financial Condition On August 6, 2024, Aquestive Therapeutics, Inc. (the "Company") issued a press release announcing its reported financial results for the second quarter ended June 30, 2024 and provided an update on recent developments in its business. A copy of the Company's press release and the attached financial schedules are attached as Exhibit 99.1 to this Current Report On Form 8-K and incorporated in this Item 2.02 by reference. The information in this Item 2.02 (including Exhibit 99.1) shall not be deemed to be "filed" for purposes of, or otherwise subject to the liabilities of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended (the "33 Act"), or the Exchange Act, except as shall be expressly set forth by specific reference in any such filing.

01

Item 7.01 Regulation FD Disclosure. The Company is furnishing this Current Report on Form 8-K in connection with the disclosure of information, in the form of a investor presentation, to be given at meetings with institutional investors, analysts and others. This information may be amended or updated at any time and from time to time through another Current Report on Form 8-K, a later Company filing or other means. A copy of the Company's investor presentation is attached hereto as Exhibits 99.2 to this Current Report on Form 8-K and incorporated into this Item 7.01 by reference. The investor presentation is available on the Company's website located at www.aquestive.com, although the Company reserves the right to discontinue that availability at any time. The information in this Item 7.01 (including Exhibit 99.2) shall not be deemed to be "filed" for purposes of, or otherwise subject to the liabilities of Section 18 of the Exchange Act, nor shall it be deemed to be incorporated by reference in any filing under the 33 Act or the Exchange Act, except as shall be expressly set forth by specific reference in any such filing.

Financial Statements and Exhibits

Financial Statements and Exhibits (d)Exhibits. Exhibit Number Description 99.1 Press Release, dated August 6, 2024, announcing the Company's reported financial results for the second quarter ended June 30, 2024 and providing an update on recent developments in its business. 99.2 Aquestive Therapeutics Q2 Earnings Supplemental Materials dated August 6, 2024. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated:August 6 , 2024 Aquestive Therapeutics, Inc. By: /s/ A. Ernest Toth, Jr Name: A. Ernest Toth, Jr. Title: Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR